Schedule a meeting with us!

por Asphalion

Are you developing a drug and need help with regulatory affairs?

Leer más

Next Stop, the Clinic - Preparing your new Drug for Clinical Research with SciFindern and Formulus®

por CAS, a division of the American Chemical Society

Things are going well for your latest drug molecule - it seems efficacious, you have assessed potential toxicity, and even determined a safe starting dose, and now you are ready to move to the clinic...

Leer más

FreeOx acquires the patent for the drug Ox-01 in the US for ischaemic stroke

por CataloniaBio

FreeOx Biotech, a CataloniaBio & HealthTech member, has been granted a patent for its most advanced drug, Ox-01, by the United States Patent and Trademark Office (USPTO). The patent protects the use o...

Leer más

Promega Developing OncoMate™ MSI Assay as Companion Diagnostic for Endometrial Cancer Drug Candidate from Incyte

por Promega Biotech Ibérica

Promega Corporation announced today its intent to develop the Promega OncoMate™ microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, Incyte’s anti-PD-1 drug cand...

Leer más

Palobiofarma announces positive results from the Phase II clinical trial evaluating the preliminary efficacy and safety of its adenosine A1 receptor antagonist PBF-680 in mild to moderate asthmatics patients

por Palobiofarma

The results confirm a clinically and statistically significant improvement in trough FEV1 of asthmatic patients taking 10mg of PBF-680 for 14 days compared to placebo.

Leer más

Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis

por Galchimia

We are happy to share our latest report from the work carried out in collaboration with GlaxoSmithKline and the Drug Discovery Unit of the University of Dundee. The paper published in RSC Medicinal Ch...

Leer más

Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD

por Minoryx Therapeutics

Leriglitazone (MIN-102), a novel, brain penetrant, orally bioavailable and selective PPARγ agonist, is currently in late-stage development for treatment of severe orphan CNS disorders, including X-AL...

Leer más

FDA aims to start deactivating outdated drug listing records to ensure the patient safety

por Asphalion

The Food and Drug Administration (FDA) announced its intention to clean the drug listing database from outdated and uncertified records. This action is not limited only to listings for finished drug p...

Leer más
Subscribirse al Directorio
Escribir un Artículo

Últimas Noticias

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...


Entrevista con Dámaso Molero, director ...

by 3P Biopharmaceuticals

Dámaso Molero:" Creo que en Latinoamérica habrá negocio en el d...

Un mapa de la expresión de los genes en...

by Hospital de la Santa Creu i Sant Pau

​Un trabajo publicado en Cell Reports descifra el mapa transcriptóm...

Diapositiva de Fotos